Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 2
2004 1
2005 3
2006 2
2007 3
2008 4
2009 4
2010 6
2011 7
2012 1
2013 5
2014 5
2015 2
2016 1
2017 1
2018 2
2019 1
2022 2
2023 1

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Pegvisomant in acromegaly: an update.
Giustina A, Arnaldi G, Bogazzi F, Cannavò S, Colao A, De Marinis L, De Menis E, Degli Uberti E, Giorgino F, Grottoli S, Lania AG, Maffei P, Pivonello R, Ghigo E. Giustina A, et al. J Endocrinol Invest. 2017 Jun;40(6):577-589. doi: 10.1007/s40618-017-0614-1. Epub 2017 Feb 7. J Endocrinol Invest. 2017. PMID: 28176221 Free PMC article. Review.
BACKGROUND: In 2007, we published an opinion document to review the role of pegvisomant (PEG) in the treatment of acromegaly. Since then, new evidence emerged on the biochemical and clinical effects of PEG and on its long-term efficacy and safety. ...The number of patients …
BACKGROUND: In 2007, we published an opinion document to review the role of pegvisomant (PEG) in the treatment of acromegaly. Since t …
Are there country-specific differences in the use of pegvisomant for acromegaly in clinical practice? An analysis from ACROSTUDY.
Grottoli S, Bianchi A, Bogazzi F, Bona C, Carlsson MO, Colao A, Dassie F, Giampietro A, Gomez R, Granato S, Maffei P, Pivonello R, Prencipe N, Ragonese M, Urbani C, Cannavò S. Grottoli S, et al. J Endocrinol Invest. 2022 Aug;45(8):1535-1545. doi: 10.1007/s40618-022-01789-4. Epub 2022 Mar 31. J Endocrinol Invest. 2022. PMID: 35359232 Free PMC article.

OBJECTIVE: A comprehensive picture of pegvisomant use for treating acromegaly in routine clinical practice in different countries is lacking. ...In all countries, the percentage of patients with normal IGF-1 increased steeply from < 20% at baseline to 43-58% at month 6

…
OBJECTIVE: A comprehensive picture of pegvisomant use for treating acromegaly in routine clinical practice in different countries is …
The beneficial effect of acromegaly control on blood pressure values in normotensive patients.
Sardella C, Urbani C, Lombardi M, Nuzzo A, Manetti L, Lupi I, Rossi G, Del Sarto S, Scattina I, Di Bello V, Martino E, Bogazzi F. Sardella C, et al. Clin Endocrinol (Oxf). 2014 Oct;81(4):573-81. doi: 10.1111/cen.12455. Epub 2014 May 5. Clin Endocrinol (Oxf). 2014. PMID: 24661019
OBJECTIVE: Control of acromegaly may ameliorate blood pressure (BP) in hypertensive (HT) patients. ...MEASUREMENTS: Blood pressure was measured by clinical measurement and 24-h ambulatory monitoring at diagnosis and after 24 months of medical therapy for acromegaly. …
OBJECTIVE: Control of acromegaly may ameliorate blood pressure (BP) in hypertensive (HT) patients. ...MEASUREMENTS: Blood pressure wa …
Effects of medical therapies for acromegaly on glucose metabolism.
Urbani C, Sardella C, Calevro A, Rossi G, Scattina I, Lombardi M, Lupi I, Manetti L, Martino E, Bogazzi F. Urbani C, et al. Eur J Endocrinol. 2013 Jun 7;169(1):99-108. doi: 10.1530/EJE-13-0032. Print 2013 Jul. Eur J Endocrinol. 2013. PMID: 23660641
Among 50 consecutive acromegalic patients under SSA therapy, acromegaly in 19 patients was controlled. PEG used in combination with SSA therapy allowed the control of acromegaly in the remaining 31 patients and was then continued as monotherapy in 18 patients. ...Co …
Among 50 consecutive acromegalic patients under SSA therapy, acromegaly in 19 patients was controlled. PEG used in combination with S …
Conventional X-rays in the diagnosis and follow-up of vertebral fractures in patients with acromegaly: a real-life study.
Sardella C, Urbani C, Marconcini G, Cappellani D, Manetti L, De Liperi A, Romei C, Morganti R, Marcocci C, Bogazzi F. Sardella C, et al. J Endocrinol Invest. 2023 Sep 5. doi: 10.1007/s40618-023-02148-7. Online ahead of print. J Endocrinol Invest. 2023. PMID: 37668886
RESULTS: At diagnosis of acromegaly, chest X-ray revealed that 10 (17%) patients had VFs. Of the 50 patients without VFs at diagnosis of acromegaly, 33 (66%) remained unfractured at the last clinical visit (median [IQR] time, 144 [96-192] months after the diagnosis …
RESULTS: At diagnosis of acromegaly, chest X-ray revealed that 10 (17%) patients had VFs. Of the 50 patients without VFs at diagnosis …
ACROSTUDY: the Italian experience.
Grottoli S, Maffei P, Bogazzi F, Cannavò S, Colao A, Ghigo E, Gomez R, Graziano E, Monterubbianesi M, Jonsson P, De Marinis L. Grottoli S, et al. Endocrine. 2015 Feb;48(1):334-41. doi: 10.1007/s12020-014-0393-9. Epub 2014 Aug 23. Endocrine. 2015. PMID: 25150035
ACROSTUDY is a world-wide non-interventional, post marketing surveillance study performed to monitor the safety and outcomes of pegvisomant (PEG) in clinical practice. We report data from acromegaly patients who have been included in the Italian ACROSTUDY registry. The dat …
ACROSTUDY is a world-wide non-interventional, post marketing surveillance study performed to monitor the safety and outcomes of pegvisomant …
Correction to: Pegvisomant in acromegaly: an update.
Giustina A, Arnaldi G, Bogazzi F, Cannavò S, Colao A, De Marinis L, De Menis E, Degli Uberti E, Giorgino F, Grottoli S, Lania AG, Maffei P, Pivonello R, Ghigo E. Giustina A, et al. J Endocrinol Invest. 2018 Feb;41(2):267. doi: 10.1007/s40618-017-0800-1. J Endocrinol Invest. 2018. PMID: 29285678 Free PMC article.
Acromegaly: effects on bone metabolism and mass.
Bogazzi F, Cosci C, Sardella C, Martino E, Gasperi M. Bogazzi F, et al. J Endocrinol Invest. 2005;28(10 Suppl):33-5. J Endocrinol Invest. 2005. PMID: 16550720 Review.
Analysis of voice in patients with untreated active acromegaly.
Bogazzi F, Nacci A, Campomori A, La Vela R, Rossi G, Lombardi M, Fattori B, Bartalena L, Ursino F, Martino E. Bogazzi F, et al. J Endocrinol Invest. 2010 Mar;33(3):178-85. doi: 10.1007/BF03346578. J Endocrinol Invest. 2010. PMID: 20418653
BACKGROUND: Voice changes are common clinical findings of acromegaly, although scanty data are available so far. OBJECTIVE: To analyze features and quantify changes of voice in patients with untreated active acromegaly. ...PATIENTS: Thirteen consecutive patients (8 …
BACKGROUND: Voice changes are common clinical findings of acromegaly, although scanty data are available so far. OBJECTIVE: To analyz …
Global psychological assessment with the evaluation of life and sleep quality and sexual and cognitive function in a large number of patients with acromegaly: a cross-sectional study.
Pivonello R, Auriemma RS, Delli Veneri A, Dassie F, Lorusso R, Ragonese M, Liotta M, Sala E, Zarino B, Lai E, Urbani C, Bogazzi F, Mantovani G, Cannavò S, Maffei P, Chiodini P, Colao A. Pivonello R, et al. Eur J Endocrinol. 2022 Dec 13;187(6):823-845. doi: 10.1530/EJE-22-0263. Print 2022 Dec 1. Eur J Endocrinol. 2022. PMID: 36165745 Free PMC article.
OBJECTIVE: Acromegaly is associated with somatic disfigurements which impair self-perception of well-being and quality of life. ...The study aimed at investigating the psychological profile, sleep quality, sexual function, cognitive functions, and quality of life in patien …
OBJECTIVE: Acromegaly is associated with somatic disfigurements which impair self-perception of well-being and quality of life. ...Th …
48 results